Effect of sleep apnoea interventions on multiple health outcomes: an umbrella review of meta-analyses of randomised controlled trialsResearch in context [PDF]
EClinicalMedicineSummary: Background: Obstructive sleep apnoea (OSA) is a prevalent chronic condition that is associated with cardiometabolic and neurocognitive complications.
Camille Figard +7 more
doaj +2 more sources
Obstructive Sleep Apnoea Treatments-Where Are We Now? [PDF]
RespirologyRespirology, Volume 30, Issue 10, Page 920-922, October 2025.
Luu S, Lee D, Yee BJ.
europepmc +2 more sources
Comparison of Solriamfetol and Modafinil on Arousal and Anxiety-Related Behaviors in Narcoleptic Mice. [PDF]
Neurotherapeutics, 2023 Wake-promoting agents are used for the management of excessive daytime sleepiness caused by narcolepsy. Clinical and preclinical data suggests that solriamfetol, a novel dopamine and norepinephrine reuptake inhibitor, is a promising therapeutic option for excessive daytime sleepiness.
Sakai N, Nishino S.
europepmc +3 more sources
Comorbidity of obstructive sleep apnea and narcolepsy: A challenging diagnosis and complex management [PDF]
Sleep Medicine: XIntroduction: Narcolepsy and obstructive sleep apnea syndrome (OSA) are relevant causes of excessive daytime sleepiness (EDS); although different for etiopathogenesis and symptoms, differential diagnosis is sometimes difficult, and guidelines are lacking
Silvia Miano +2 more
doaj +2 more sources
Solriamfetol enhances alertness and cognitive performance in mice
Abstract Solriamfetol [(R)-2-amino-3-phenylpropylcarbamate hydrochloride], a phenylalanine derivative initially developed as potential antidepressant, was shown by our group in 2009 to have potent, dose-dependent wake-promoting activity in mice.
Haddar M +4 more
europepmc +2 more sources
A Review of Current and Future Pharmacologic Treatments for Narcolepsy [PDF]
European PsychiatryIntroduction Narcolepsy is a rare but disabling neurological disorder involving disruption of the sleep-wake cycle that is often under- or misdiagnosed (Barateau L, et al. J Sleep Res. 2022;31(4):e13631).
P. Chue +4 more
doaj +2 more sources
A Comprehensive Review of Solriamfetol to Treat Excessive Daytime Sleepiness. [PDF]
Psychopharmacol BullPurpose of Review This is a comprehensive review of the literature regarding the use of Solriamfetol for excessive daytime sleepiness. It covers the background and current therapeutic approaches to treating excessive daytime sleepiness, the management of common comorbidities, and the existing evidence investigating the use of Solriamfetol for this ...
Fuller MC +10 more
europepmc +3 more sources
481 Solriamfetol Titration & AdministRaTion (START): Characteristics of patients with narcolepsy and solriamfetol prescriber rationale [PDF]
Sleep, 2021 Abstract Introduction Pharmacotherapy for excessive daytime sleepiness (EDS) associated with narcolepsy is diverse, with factors such as efficacy, side effects, and tolerance influencing treatment decisions.
Michael Thorpy +6 more
openaire +2 more sources
P148 Solriamfetol Titration & AdministRaTion (START): Dosing and titration strategies in patients with narcolepsy starting solriamfetol [PDF]
SLEEP Advances, 2021 Abstract Introduction Solriamfetol (Sunosi) is a dopamine/norepinephrine reuptake inhibitor approved (EU/US) to treat excessive daytime sleepiness (EDS) in adults with narcolepsy (75–150 mg/day) or obstructive sleep apnoea (OSA) (37.5–150 mg/day).
Thorpy, M +6 more
openaire +1 more source
Solriamfetol for the Use of Narcolepsy: A Systematic Review
Cureus, 2022 Narcolepsy is a chronic and disabling neurological disorder characterized by excessive daytime sleepiness (EDS) and cataplexy. Historically, some medications have demonstrated efficacy in managing EDS and cataplexy symptoms. However, some patients cannot tolerate them, become refractory, or may use concomitant medications that preclude the use due to ...
Iturburu, Alisson +9 more
openaire +2 more sources